jRCT2031230115进行中（未招募）不适用
A phase II clinical trial of KNP2002 ointment in patients with common warts
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 160
- 主要终点
- Adverse event
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 15age old over 至 50age old not（—）
- 性别
- All
入选标准
- •Subjects aged 15 to 49 at the time of obtaining consent
- •Subjects with typical common warts on the upper extremities or lower extremities excluding the soles of the feet.
- •Subjects who agree to contraception from obtaining consent to 4 weeks after the end of administration
- •Subjects who have given their voluntary written consent to participate in this clinical trial
排除标准
- •Subjects with 5 or more warts due to human papillomavirus (HPV) infection on the upper or lower limbs
- •Subjects who are scheduled to undergo treatment such as physical therapy or chemotherapy for warts
- •Subjects with a history of allergy to topical skin preparations
- •Subjects with a history of malignant tumor within 5 years before administration of study drug
- •Subjects with any of the following diseases
- •Malignant tumor
- •Serious heart disease
- •Poorly controlled diabetes, hypertension
- •Women who are pregnant, may become pregnant, or are breastfeeding.
结局指标
主要结局
Adverse event
Safety evaluation items
Wart area change from the start of administration (at endpoint)
Efficacy endpoints
次要结局
未报告次要终点
研究者
相似试验
招募中
2 期
A phase II clinical trial of KNP2002 ointment in patients with common wartsJPRN-jRCT2031230115Sato Katsuhiko160
未知
2 期
K012 phase II clinical studyColorectal cancerJPRN-jRCT2080220752ippon Kayaku Co., Ltd.
进行中（未招募）
1 期
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregional or metastatic breast carcinoma which has progressed on prior trastuzumab-based therapy.A parallel cohort of 15 patients with HER2-positive, PD-L1 negative disease will be enrolled in the phase II study.MedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-ATInternational Breast Cancer Study Group (IBCSG)61
进行中（未招募）
1 期
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregionalor metastatic breast carcinoma which has progressed on priortrastuzumab-based therapyMedDRA version: 17.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-ITInternational Breast Cancer Study Group (IBCSG)58
进行中（未招募）
1 期
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregional or metastatic breast carcinoma which has progressed on prior trastuzumab-based therapy.A parallel cohort of 15 patients with HER2-positive, PD-L1 negative disease will be enrolled in the phase II study.MedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-BEInternational Breast Cancer Study Group (IBCSG)61